Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
213.20
+1.31 (+0.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
39
40
Next >
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much
May 31, 2022
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.1% on an annualized basis producing an average annual return of 10.04%. Currently, Biogen has a market capitalization of...
Via
Benzinga
Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
May 23, 2022
Catalyst Biosciences (CBIO) stock is rocketing higher on Monday after announcing the sale of its protease medicines portfolio.
Via
InvestorPlace
Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex
May 23, 2022
Via
Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 23
May 23, 2022
CNBC US Announces Asia Economic Deal To Strengthen Foothold, Check China
Via
Benzinga
Read Why Biogen Sares Are Trading Higher After Q1 Earnings
May 03, 2022
Via
Benzinga
Biogen Pops On New Plans For Its Embattled Alzheimer's Drug, Aduhelm
May 03, 2022
The decision comes after Medicare officials severely limited coverage of Aduhelm.
Via
Investor's Business Daily
Recap: Biogen Q1 Earnings
May 03, 2022
Biogen (NASDAQ:BIIB) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Researchers Investigate New Treatment Pathways For Alzheimer's After Commercial Failure Of Biogen's Aduhelm
May 23, 2022
The commercial failure of Biogen Inc's (NASDAQ: BIIB) drug Aduhelm has put a new focus on the research into the causes of Alzheimer's disease.
Via
Benzinga
Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment
May 10, 2022
Eisai finished submitting its application for lecanemab, another anti-amyloid drug.
Via
Investor's Business Daily
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Biogen Fails To Convince Benefits Of Alzheimer's Drug To European Regulator
April 22, 2022
Via
Benzinga
Why Biogen Stock Looks 'Too Good To Ignore,' According To One Analyst
April 18, 2022
Biogen stock could see a resurgence later this year, according to one analyst.
Via
Investor's Business Daily
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
May 10, 2022
Via
Benzinga
Stock Market Jumps, Then Dives After Fed Rate Hikes As Treasury Yields Soar: Weekly Review
May 06, 2022
Lithium plays jump on earnings, but Nasdaq at lowest level since 2020.
Via
Investor's Business Daily
Looking Into Biogen's Return On Capital Employed
May 04, 2022
According to Benzinga Pro, during Q1, Biogen (NASDAQ:BIIB) earned $218.50 million, a 1165.85% increase from the preceding quarter. Biogen's sales decreased to $2.53 billion, a 7.39% change since Q4.
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
May 04, 2022
RBC Capital boosted Atkore Inc. (NYSE: ATKR) price target from $123 to $170. Atkore shares rose 0.2% to $109.00 in pre-market trading.
Via
Benzinga
BIIB Stock Treks Higher Amid News That Biogen CEO Michel Vounatsos Is Stepping Down
May 03, 2022
Drug-making giant Biogen is in the green today after announcing CEO Michel Vounatsos is stepping down from the role.
Via
InvestorPlace
Biogen Inc. Q1 Earnings Miss Estimates
May 03, 2022
Biogen Inc. came out with quarterly earnings of $3.62 per share.
Via
Talk Markets
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder
May 02, 2022
Via
Benzinga
Earnings Preview For Biogen
May 02, 2022
Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report an...
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
If You Invested $100 In Biogen 15 Years Ago, Here's How Much You Would Have Today
April 22, 2022
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.88% on an annualized basis producing an average annual return of 11.31%. Currently, Biogen has a market capitalization of...
Via
Benzinga
Analyst Ratings for Biogen
April 21, 2022
Over the past 3 months, 15 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Biogen Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 21, 2022
Biogen (NASDAQ:BIIB) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
Why This Analyst Believes Biogen Is 'Too Good to Ignore'
April 18, 2022
Biogen Inc’s (NASDAQ: BIIB) base business seems to be worth more than what the Street estimates, and it is possible that investors are not properly valuing royalty streams coming to the company, which...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
April 18, 2022
Upgrades
Via
Benzinga
Biogen’s Aduhelm Crashes the Biotech Sector
April 13, 2022
Aduhelm's quick approval and high price have set off pushback on the whole FDA and Medicare drug process which is not good for BIIB stock.
Via
InvestorPlace
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
April 08, 2022
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now.
Via
InvestorPlace
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.